AIM2 and myocarditis: Recently, promoting an adaptive response with an AIM2‐adjuvanted vaccine has demonstrated therapeutic efficacy, relieving the symptoms of coxsackievirus B3‐induced myocarditis and renal carcinoma.40, 129 Thus, AIM2 is a potential therapeutic target for cancer treatment.